Profile data is unavailable for this security.
About the company
Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
- Revenue in GBP (TTM)204.71m
- Net income in GBP-143.34m
- Incorporated2005
- Employees1.33k
- LocationOxford Nanopore Technologies PLCOxford Science ParkGosling Building, Edmund Halley RoadOXFORD OX4 4DQUnited KingdomGBR
- Websitehttps://www.nanoporetech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paul Hartmann AG | 2.11bn | 70.92m | 686.96m | 10.09k | 9.63 | 0.6696 | 4.10 | 0.3254 | 22.95 | 22.95 | 682.93 | 330.05 | 1.16 | 1.97 | 5.54 | 240,745.70 | 4.12 | 4.21 | 5.45 | 5.79 | 59.56 | 57.30 | 3.56 | 3.35 | 1.11 | 14.11 | 0.2465 | 37.95 | 2.32 | 1.95 | 281.58 | 13.23 | 10.08 | 2.71 |
| Gerresheimer AG | 1.96bn | 20.32m | 794.12m | 13.54k | 39.41 | 0.6564 | 3.27 | 0.4056 | 0.676 | 0.676 | 65.15 | 40.59 | 0.5455 | 3.73 | 7.85 | 185,328.90 | 0.6341 | 3.30 | 0.8716 | 4.68 | 26.89 | 30.04 | 1.16 | 5.84 | 0.5214 | 2.08 | 0.6022 | 41.29 | 2.28 | 7.90 | -5.52 | 6.32 | 17.58 | -49.35 |
| ChemoMetec A/S | 57.43m | 20.62m | 824.88m | 172.00 | 40.01 | 10.85 | 34.65 | 14.36 | 10.17 | 10.17 | 28.33 | 37.50 | 0.6516 | 0.6662 | 5.54 | 2,679,973.00 | 23.39 | 27.48 | 27.93 | 34.02 | 83.83 | 80.53 | 35.90 | 36.41 | 3.06 | 95.21 | 0.0079 | 48.77 | 21.50 | 18.28 | 36.78 | 25.80 | 19.35 | 36.08 |
| Eckert & Ziegler SE | 264.93m | 35.35m | 825.53m | 1.11k | 23.29 | 4.07 | 16.61 | 3.12 | 0.6465 | 0.6328 | 4.85 | 3.70 | 0.6527 | 3.48 | 6.10 | 280,619.30 | 8.85 | 8.62 | 11.06 | 10.43 | 47.25 | 48.53 | 13.55 | 14.18 | 2.37 | 68.35 | 0.166 | 32.12 | 20.22 | 10.63 | 33.40 | 12.70 | 18.84 | 3.30 |
| Vitrolife AB | 281.50m | -410.26m | 990.62m | 1.15k | -- | 1.53 | -- | 3.52 | -37.01 | -37.01 | 25.39 | 58.29 | 0.2407 | 3.44 | 5.24 | 2,987,837.00 | -35.09 | -9.46 | -36.79 | -9.86 | 58.24 | 57.81 | -145.74 | -49.19 | 2.73 | 11.33 | 0.169 | -- | -4.68 | 22.53 | -1,077.00 | -- | 68.15 | 6.58 |
| El En SpA | -87.01bn | -87.01bn | 993.21m | 1.42k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.88 | -- | 13.94 | -- | 40.32 | -- | 8.90 | -- | -- | -- | 27.62 | -1.76 | 7.14 | 16.06 | 18.96 | -17.09 | -- |
| Medartis Holding AG | 225.27m | -464.18k | 1.17bn | 1.16k | -- | 4.29 | 54.03 | 5.21 | -0.0344 | -0.0344 | 20.25 | 21.03 | 0.5082 | 0.5986 | 5.33 | 249,045.30 | -0.0828 | 0.2609 | -0.0953 | 0.2945 | 79.11 | 81.17 | -0.1629 | 0.4695 | 3.57 | 2.11 | 0.3234 | 0.00 | 6.05 | 11.55 | 469.95 | 10.45 | -10.60 | -- |
| SKAN Group AG | 316.57m | 15.42m | 1.21bn | 1.50k | 78.53 | 7.17 | 42.57 | 3.82 | 0.7195 | 0.7195 | 14.77 | 7.88 | 0.9052 | 0.709 | 15.33 | 241,201.20 | 4.86 | 7.69 | 9.28 | 16.03 | 74.38 | 72.97 | 5.37 | 8.89 | 0.524 | 16.87 | 0.0518 | 28.09 | 12.90 | 80.51 | 47.47 | 16.66 | -- | -- |
| Draegerwerk AG & Co KGaA | 2.98bn | 105.18m | 1.26bn | 16.68k | 10.89 | 0.8714 | 5.42 | 0.4244 | 6.45 | 6.45 | 182.35 | 80.56 | 1.13 | 2.51 | 5.01 | 206,009.00 | 4.00 | 3.72 | 5.94 | 5.59 | 45.35 | 44.54 | 3.53 | 3.49 | 1.03 | 7.96 | 0.1637 | 16.12 | -0.0778 | 3.92 | 12.65 | 37.91 | 0.4683 | 59.64 |
| Oxford Nanopore Technologies PLC | 204.71m | -143.34m | 1.36bn | 1.33k | -- | 2.59 | -- | 6.66 | -0.1515 | -0.1515 | 0.2164 | 0.5446 | 0.2936 | 0.8608 | 3.25 | 155,672.30 | -20.56 | -19.53 | -24.11 | -22.70 | 57.32 | 55.04 | -70.02 | -77.67 | 3.89 | -- | 0.0777 | -- | 7.97 | 28.61 | 5.38 | -- | 9.93 | -- |
| AddLife AB | 854.73m | 45.84m | 1.43bn | 2.30k | 32.14 | 3.31 | 12.70 | 1.67 | 4.60 | 4.60 | 85.69 | 44.66 | 0.8105 | 3.83 | 5.87 | 4,549,891.00 | 4.36 | 3.82 | 6.05 | 5.80 | 38.09 | 37.80 | 5.38 | 4.66 | 0.6257 | 3.68 | 0.4671 | 31.71 | 1.52 | 14.64 | 122.22 | 1.58 | 22.47 | 0.00 |
| Embla Medical hf | 678.13m | 60.85m | 1.55bn | 4.19k | 25.21 | 2.36 | 14.68 | 2.28 | 1.22 | 1.22 | 13.62 | 13.05 | 0.5681 | 2.27 | 6.96 | 1,389,003.00 | 5.12 | 4.60 | 6.10 | 5.43 | 62.30 | 62.25 | 9.01 | 7.99 | 0.9445 | 7.22 | 0.3768 | 0.00 | 8.63 | 8.09 | 22.05 | 68.07 | 6.12 | -- |
| Elekta AB (publ) | 1.44bn | 23.90m | 1.66bn | 4.48k | 72.13 | 2.49 | 12.88 | 1.16 | 0.7646 | 0.7646 | 45.97 | 22.11 | 0.5781 | 3.35 | 3.09 | 3,872,796.00 | 0.9511 | 3.48 | 1.70 | 6.21 | 38.17 | 38.22 | 1.65 | 6.02 | 0.7918 | 7.51 | 0.4724 | 92.20 | -0.5685 | 4.29 | -81.80 | -26.22 | 15.56 | 5.92 |
| SCHOTT Pharma AG & Co KgaA | 858.12m | 127.43m | 1.84bn | 4.81k | 14.56 | 2.39 | 9.12 | 2.14 | 0.9724 | 0.9724 | 6.55 | 5.92 | 0.6496 | 4.07 | 3.89 | 204,990.60 | 9.68 | 11.86 | 13.71 | 16.87 | 33.71 | 34.65 | 14.90 | 15.68 | 1.12 | -- | 0.0874 | 10.95 | 3.04 | 11.04 | -2.16 | 13.58 | 11.15 | -- |
Data as of Feb 10 2026. Currency figures normalised to Oxford Nanopore Technologies PLC's reporting currency: UK Pound GBX
21.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 10 Jun 2025 | 47.73m | 4.94% |
| Natixis Investment Managers International SAas of 01 Jan 2026 | 41.48m | 4.30% |
| Storebrand Asset Management ASas of 01 Jan 2026 | 35.29m | 3.65% |
| Lansdowne Partners (UK) LLPas of 29 Feb 2024 | 25.70m | 2.66% |
| Aberforth Partners LLPas of 01 Jan 2026 | 13.45m | 1.39% |
| Citibank (Switzerland) AGas of 01 Jan 2026 | 13.12m | 1.36% |
| ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 30 Nov 2025 | 8.20m | 0.85% |
| T. Rowe Price Hong Kong Ltd.as of 30 Sep 2025 | 7.79m | 0.81% |
| The Vanguard Group, Inc.as of 01 Jan 2026 | 7.39m | 0.77% |
| Bessemer Investment Management LLCas of 01 Jan 2026 | 6.79m | 0.70% |
More ▼
Data from 30 Sep 2025 - 02 Feb 2026Source: FactSet Research Systems Inc.
